Trexquant Investment LP Fibrogen Inc Transaction History

Trexquant Investment LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $718,260 - $1.13 Million	45,032 New	45,032 $840,000
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $233,704 - $326,447	-19,443 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $237,466 - $368,036	-23,914 Reduced 55.16%	19,443 $274,000
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $441,374 - $1.16 Million	43,357 New	43,357 $443,000
Q4 2020 Feb 11, 2021	SELL	$37.09 - $48.97 $848,359 - $1.12 Million	-22,873 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$40.47 - $45.5 $925,670 - $1.04 Million	22,873 New	22,873 $941,000
Q2 2019 Aug 09, 2019	SELL	$35.13 - $55.53 $590,078 - $932,737	-16,797 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$42.83 - $59.91 $719,415 - $1.01 Million	16,797 New	16,797 $913,000
Q4 2018 Feb 13, 2019	SELL	$37.97 - $60.16 $125,908 - $199,490	-3,316 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$56.3 - $67.25 $186,690 - $223,001	3,316 New	3,316 $201,000
Q1 2018 May 03, 2018	SELL	$45.35 - $61.65 $869,994 - $1.18 Million	-19,184 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$41.95 - $60.1 $804,768 - $1.15 Million	19,184	19,184 $909,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.